Is GLP-1R Agonists Effective and Safe in Severe COVID-19 Patients with Type 2 Diabetes? - A Case Report and Literature Review
8 Pages Posted: 29 Jul 2020
Date Written: July 17, 2020
Abstract
Hyperglycemia is a risk factor for the severity of COVID-19. Glucagon-like Peptide 1 Receptor (GLP-1R) agonists have been proved to be a safe and effective anti-hyperglycemia drugs. This paper introduces a case of severe COVID-19 patient combined with diabetes and try to study the safety and efficacy of liraglutide in these patients. During treatment, dynamic change of blood glucose level was shown in the Figure 1. Hydroxychloroquine sulfate and abidol was used to antivirus and supportive treatment were used simultaneously during hospitalization. Dynamic change of liver function, renal function, white blood cells, lymphocytes and inflammatory indicators during treatment were shown in Figure 2 and Figure 3. The patient's condition improve gradually, blood glucose was under control, the laboratory test and chest CT also improved after treatment. (Fig4) This case indicates that liraglutide can be safely used in patients with severe COVID-19 combined with type 2 diabetes.
Note: Funding: None.
Conflict of Interest: The authors declare that they have no conflicts of interest for this work.
Suggested Citation: Suggested Citation